Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Better Biosynthesis Building Blocks

Bacterium genome analysis turns up a novel pathway to salinosporamide anticancer agents that may have general biosynthesis applications

by Carmen Drahl
July 27, 2009 | A version of this story appeared in Volume 87, Issue 30

A pair of biosynthetic studies may provide information that makes it easier to access analogs of the salinosporamides, a promising class of anticancer agents. Bradley S. Moore of Scripps Institution of Oceanography and the University of California, San Diego, teamed with Kevin A. Reynolds of Portland State University and colleagues to analyze the genome of Salinispora tropica, a deep-sea-dwelling bacterium that makes salinosporamides. They found that salinosporamides are biosynthesized by an unusual polyketide synthase (PKS) enzyme (Proc. Natl. Acad. Sci. USA, DOI: 10.1073/pnas.0901237106). The team then explored the enzyme's substrate specificity and learned that it can incorporate a broad range of substrates, including brominated and fluorinated compounds, into the salinosporamide skeleton (J. Am. Chem. Soc., DOI: 10.1021/ja9042824). PKS enzymes naturally make erythromycin, rapamycin, and a host of other drugs. They tend to accept a limited set of substrates, however, leaving few opportunities for further elaboration. In contrast, the salinosporamide-making PKS accepts substrates with functionalizable moieties, which might aid efforts to generate novel drug derivatives via fermentation, says Yi Tang, who studies biosynthesis at UCLA.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.